Table 1.
Demographic information and baseline characteristics
| Parameter | Participants (n=220) No. (%) |
|---|---|
| Age (years) | |
| Median (range) | 49 (34-66) |
| Ethnic background | |
| West and South European | 215 (98) |
| African | 2 (1) |
| Asian | 3 (1) |
| CTCAE* V4.0 Alopecia Grade 0 at baseline CTCAE* V4.0 Alopecia Grade 1 at baseline |
212 (96) 8 (4) |
| Study site | |
| 1 | 150 (68) |
| 2 | 40 (18) |
| 3 | 30 (14) |
| Planned chemotherapy regimen | |
| AC: doxorubicin, 60 mg/mq and cyclophosphamide, 600 mg/mq (4 cycles every 3 weeks) | 59 (27) |
| AC followed by paclitaxel, 80 mg/mq weekly for 4 cycles | 22 (10) |
| EC: epirubicin, 90 mg/mq and cyclophosphamide, 600 mg/mq (4 cycles every 3 weeks) | 20 (9) |
| EC followed by paclitaxel, 80 mg/mq weekly for 4 cycles | 11 (6) |
| FEC: 5-fluorouracil, 500 mg/mq, epirubicin, 75-90-100 mg/mq and cyclophosphamide, 500 mg/mq (4 cycles every 3 weeks) | 19 (8) |
| FEC 3-4 cycles followed by docetaxel, 100 mg/mq (3 cycles every 3 weeks) | 31 (14) |
| DC: docetaxel, 75 mg/mq with cyclophosphamide, 600 mg/mq (4-6 cycles every 3 weeks) | 21 (9) |
| Paclitaxel, 80 mg/mq weekly for 4 cycles | 28 (13) |
| Docetaxel, 100 mg/mq weekly for 3 cycles | 9 (4) |
| Scalp cooling sessions | |
| Median (range) | 8 (1-16) |
*CTCAE: Common Terminology Criteria for Adverse Events